Thursday, November 30, 2006

Biotech News - Scan of Entire Human Genome Finds Unexpected New Clues on Lou Gehrig�s Disease

Scan of Entire Human Genome Finds Unexpected New Clues on Lou Gehrig's Disease

 

11-30-2006

TUCSON, Ariz., Nov. 30, 2006 -- A comprehensive scan of the human genome has identified more than 50 genetic abnormalities in people with sporadic amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease), the Muscular Dystrophy Association (MDA) and the Translational Genomics Research Institute (TGEN) announced today. The most common of these abnormalities have never before been shown to play a role in the disease.
TGen researchers, announcing the findings at an international ALS conference in Japan, said the identified differences implicate genes likely to play a role in cell function that controls nerve adhesion, offering a major new avenue for ALS research. TGen researchers identified the differences by screening DNA samples from over 1,200 people with and 2,000 people without sporadic ALS using state-of-the-art microarray technology by Affymetrix of Santa Clara, Calif.

"Our findings indicate these genes produce a sort of molecular glue that attaches motor neurons to muscle. It appears that in ALS the nerve is able to peel off the muscle and, when that happens repeatedly, the nerves die," said Dietrich Stephan, TGen director of Neurogenomics and the study's principle investigator.

ALS is a progressive neurological disorder that leads to paralysis and death in three to five years. It has baffled researchers for nearly 140 years.


What is extraordinary about this study is how quickly this breakthrough occurred. A new fast-track research funding approach used by MDA and a new microarray technology by Affymetrix that lets researchers quickly scan people's genomes enabled the experiment to be completed in just nine months.

"There is a revolution going on in research, and this study is a perfect example of how things are changing," said Sharon Hesterlee, MDA vice president of translational research. "New technology is letting us look at the genome at a level of detail that was unthinkable just a few years ago and, as a result, costs are coming down, results are coming much faster and we're seeing breakthroughs in diseases that have baffled researchers for decades."


The Affymetrix 500K Arrays identified the genetic differences between the affected and unaffected groups and rapidly produced a genetic map of each individual.

"Just a couple of years ago, this experiment would not have been possible because there simply wasn't a technology that enabled scientists to sift through the three billion molecules in the genome to find the genetic abnormalities that cause disease," said Sean George, vice president Academic Business Unit at Affymetrix. "The 500K microarray used on this experiment employs the same kind of semi-conductor technology that powers super computers."

According to MDA and TGen, the next steps center around high-throughput screening for drugs that act on the biochemical pathways identified by the DNA screen.

The massive project was funded by a $652,000 grant from MDA's Augie's Quest, a fast-track ALS research program, in collaboration with TGen. Blood donated for the study came from the MDA/ALS Center at Methodist Neurological Institute in Houston, the Forbes Norris MDA/ALS Center at California Pacific Medical Center in San Francisco, the MDA/ALS Center at the University of Pittsburgh, and the Eleanor and Lou Gehrig MDA/ALS Center at Columbia University in New York, as well as a dozen other collection sites throughout the United States.

# # #

About MDA
MDA (www.mda.org) is a voluntary health agency working to defeat more than 40 neuromuscular diseases through programs of worldwide research, comprehensive services and far-reaching professional and public health education. It operates 235 neuromuscular disease clinics, of which 37 are ALS-specific research and care centers, across the United States.
In 2006, MDA allocated some $7 million to ALS research and another $10 million for ALS health care services. Since its inception, the Association's expenditures for ALS research and services have exceeded $190 million.

About Augie's Quest
Fitness pioneer Augie Nieto started Augie's Quest (www.augiesquest.org) in conjunction with MDA's ALS Division. Nieto is co-founder and former president of Life Fitness, and chairman of Octane Fitness. He and his wife, Lynne, serve as co-chairpersons of MDA's ALS Division. Nieto received a diagnosis of ALS in March 2005.

About the TGen
TGen is a nonprofit 501(c)(3) organization focused on developing earlier diagnostics and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. TGen's research is based on personalized medicine. The institute plans to accomplish its goals through robust and disease-focused research.

About Affymetrix Inc.
Affymetrix Inc. (Nasdaq:AFFX) scientists invented the world's first high-density microarray in 1989 and began selling the first commercial microarray in 1994. The microarray technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and nonprofit research institutes. More information about Affymetrix can be found at www.affymetrix.com.

 

Biotech News
Arizona Biotech

__._,_.___
Recent Activity
Visit Your Group
SPONSORED LINKS
Yahoo! News

US News

Get the latest

national news now

Be Discovered!

Yahoo! HotJobs

Employers find you

Upload your resume

Yahoo! Groups

Start a group

in 3 easy steps.

Connect with others.

.

__,_._,___

Biotech News - TGen to hold 2006 Pancreatic Cancer Research Symposium

TGen to hold 2006 Pancreatic Cancer Research Symposium

(Forum brings together national leaders in pancreatic cancer research and patients)


11-30-2006

Friday, December 1

The Translational Genomics Research Institute (TGen) will hold the 2006 Pancreatic Cancer Research Symposium in Phoenix, on Friday, December 1, 2006. The Symposium features guest speakers from Johns Hopkins University, Barrow Neurological Institute, and Massachusetts General Hospital Cancer Center and will focus on current and new therapies for pancreatic cancer patients, including vaccines, radiotherapy and new genetic findings in the laboratory.

Attendees will be given the opportunity to donate a small blood sample for future genetic research in pancreatic cancer. This collection of samples from healthy individuals will be important to genetically compare samples from pancreatic cancer patients.

The Fourth Annual Seena Magowitz Golf Classic and 5K Walk will follow the Symposium, on December 2, 2006.

Where: University of Arizona College of Medicine-Phoenix
Building 2, Main Auditorium
600 East Van Buren Street
Phoenix, AZ 85004

When: December 1, 2006
8:30 a.m.-9 a.m. – Researchers and Patients Available for Brief Interviews
9 a.m.–Noon – Symposium
Noon-1 p.m. – Lunch & Open Forum
1 p.m.–2 p.m. – Tour TGen Laboratories
2 p.m. – Adjourn

About the TGen
TGen is a nonprofit 501(c)(3) organization focused on developing earlier diagnostics and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. TGen's research is based on personalized medicine. The institute plans to accomplish its goals through robust and disease-focused research. For further information, visit www.TGen.org.

 

Arizona Biotech

Biotech News by Thread

Biotech News by Date

Arizona Entrepreneurs

__._,_.___
Recent Activity
Visit Your Group
SPONSORED LINKS
Yahoo! News

Health News

Important health

news - get it now

Yahoo! HotJobs

Find the right one

Search for jobs

across the web

Yahoo! Groups

Start a group

in 3 easy steps.

Connect with others.

.

__,_._,___

Saturday, November 25, 2006

Chandler expects biotech growth

Chandler expects biotech growth
By Chris Markham, Tribune
November 19, 2006
The Chandler City Council and the Chandler Chamber of Commerce tout Covance’s planned $125 million investment as the city’s entrée into the biotech industry, with expectations that other biotech firms will quickly follow.


“If that’s the goal of the community, I think this is a good first step,” said Mark Bugher, director of Madison, Wis.’s University Research Park, a large biotech and high-tech campus that acts as an incubator to small companies looking to put research into the marketplace.



More here

Biotechnology News

Sunday, November 19, 2006

Sentigen Holding Corp. SGHL Merger with Invitrogen Corporation IVGN

Sentigen Holding Corp. Stockholders Approve Merger with Invitrogen
Corporation

Sentigen Holding Corp. SGHL Merger with Invitrogen Corporation IVGN

Sentigen Holding Corp. (Nasdaq:SGHL) today announced that at the
special meeting of stockholders held today, Sentigen stockholders
approved the adoption of the agreement and plan of merger with
Invitrogen Corporation (Nasdaq:IVGN), a global leader in life
sciences. The transaction was approved by more than 50% of the shares
outstanding. Based on discussions to date with Invitrogen, and
contingent upon the satisfaction of specified closing conditions,
Sentigen believes that the merger with Invitrogen will be completed
within the next several weeks.

As previously announced, on August 31, 2006, Sentigen and Invitrogen
entered into a definitive merger agreement under which Invitrogen
will acquire Sentigen in a cash transaction at a price of $3.37 per
share for all shares currently issued and outstanding.

Prior to the merger, it is expected that Sentigen will distribute the
shares of SentiSearch, Inc., a newly-formed corporation, in a taxable
transaction, pro rata to the then existing stockholders of Sentigen.
SentiSearch, Inc. is expected to be a publicly traded company,
initially holding certain olfaction intellectual property previously
owned by Sentigen.

Additional Information about the proposed merger and where you can
find it

In connection with the proposed merger, Sentigen has filed a proxy
statement and other relevant materials with the Securities and
Exchange Commission ("SEC"). The proxy statement and other relevant
materials, and any other documents filed by Sentigen with the SEC,
may be obtained free of charge at the SEC's web site at www.sec.gov.

About Sentigen Holding Corp.

Sentigen Holding Corp. conducts business through two wholly-owned
operating subsidiaries: Sentigen Biosciences, Inc. ("Sentigen
Biosciences") and Cell & Molecular Technologies, Inc. ("CMT"). CMT
provides contract research and development services to companies
engaged in the drug discovery process in the following areas:
molecular and cell biology, gene expression and protein biochemistry,
bio-processing, high throughput screening support services, mouse
genetics, and cell-based GPCR selectivity profiling. Sentigen
Biosciences has been primarily engaged in the development and
commercialization of novel bioassay systems that elucidate the
underlying biology of protein-protein interactions. Sentigen
Biosciences has initially targeted its Tango™ Assay System to address
the functionalization of G protein-coupled receptors (GPCRs) for
pharmaceutical drug discovery and development. For more information
on our companies, please visit their respective websites: www.cmt-
inc.net and www.sentigen.com.

Safe Harbor Statement

This news release includes forward-looking statements that involve
risks and uncertainties. Although Sentigen believes such statements
are reasonable, it can make no assurance that such statements will
prove to be correct. Such statements are subject to certain factors
that may cause results to differ materially from the forward-looking
statements. Such factors include the risk factors discussed in
Sentigen's filings with the Securities and Exchange Commission,
including its most recent Annual Report on Form 10-K and the merger
proxy dated October 13, 2006, copies of which may be obtained from
Sentigen without charge. Sentigen undertakes no obligation to
publicly release results of any of these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unexpected results.

Bio-Matrix Scientific BMSN Receives Certificate of Compliance for Class 10,000 Processing Laboratory

Bio-Matrix Scientific Receives Certificate of Compliance for Class 10,000 Processing Laboratory
Nov 16 2006

Bio-Matrix Scientific Group Inc. (OTCBB:BMSN), a biotechnology company focused on stem cell cryogenics and disposable stem cell/tissue transfer instruments, announced today it has received its Certificate of Compliance for the new Stem Cell Class 10,000 Processing Laboratory. The certificate has been granted by the Controlled Environmental Regulatory Testing Services (CERTS), which conducts ISO certification testing.

Bio-Matrix Scientific has completed the calibration and certification of the class 10,000 clean room and has received the ISO 14644 class 7 certificate of compliance. Bio-Matrix's stem cell processing laboratory now meets Federal Air Control Regulations to operate as a Class 10,000 Clean Room.

Bio-Matrix intends to utilize state-of-the art closed processing systems to harvest stem cells in its cord blood division by obtaining stem cells from fat tissue, which is a new dimension of stem cell banking. This processing system requires several procedures that must be carried out under strictly controlled environments to minimize the risk of microbial contamination.

Bio-Matrix Chairman & CEO David Koos stated, "This certificate of compliance, which forms part of our comprehensive cGMP (good manufacturing practices) and cGTP (good tissue practices) systems, will assure our customers that their stem cells are processed and stored under safe, controlled environments."

Bio-Matrix's new 15,000-sq-ft, state-of-the-art laboratory, located in the heart of the San Diego biotechnology corridor, will house Bio-Matrix's secure Cryogenic Stem Cell Bank; three research laboratories; an aseptic cellular/tissue class 10,000/100 processing laboratory; and hematology, microbiology and flow cytometry laboratories.

This press release is available on the company's official online Investor Relations HUB at http://www.agoracom.com/IR/Bio-Matrix for investor questions, answers and monitored commentary. Alternatively, investors are able to e-mail all questions and correspondence to BMSN@agoracom.com, where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time.

About Bio-Matrix Scientific Group Inc.

Bio-Matrix Scientific Group Inc. (www.BMSNonline.com) is a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market.

The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in San Diego to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry.

DISCLAIMER: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Cephalon Inc. (CEPH) and Alkermes Inc. (ALKS) Licensing Agreement

Cephalon, Alkermes Amend Licensing Agreement

Cephalon Inc. (CEPH) and Alkermes Inc. (ALKS) amended their license and supply agreements.

Cephalon is now responsible for some costs related to the Vivitrol anti-alcoholism drug.

VASTox (AIM: VOX), a leading UK biotechnology company, announces today that it has received a grant from the Association Francaise Contre Les Myopathi

VASTox (AIM: VOX), a leading UK biotechnology company, announces today that it has received a grant from the Association Francaise Contre Les Myopathies (AFM), a leading European neuromuscular disease charity, to support to the company’s Spinal Muscular Atrophy (SMA) drug discovery programme.

VASTox has developed an innovative in vivo screen, which models SMA in fruitfly larvae (Drosophila melanogaster). The Company is using this model to identify small molecules from its proprietary compound library. The financial support from AFM will allow VASTox to accelerate the preclinical screening and candidate identification phase of the programme and consequently aid the development of a novel therapy for SMA.

Spinal Muscular Atrophy affects 50,000 people in the developed world and is a genetic disease that causes loss of motor neurons in the spinal cord resulting in muscle atrophy. Patients either do not acquire or progressively lose the ability to move and death primarily occurs due to respiratory failure. In its severest form, known as type I, life expectancy is often less than two years.

AFM is one of the largest charities in the World that focuses on neuromuscular diseases; it has raised over €1.2 billion since 1987, the majority of which has been devoted to research and development. Founded in 1958 by a group of muscular dystrophy patients and families, AFM is focused mainly on developing cures for neuromuscular diseases and reducing the disabilities they cause.

Steven Lee, PhD, CEO of VASTox said: "VASTox is delighted to receive this grant from the AFM to help us accelerate our spinal muscular atrophy drug discovery efforts, particularly following the exciting progress we announced in the SMA programme last month. It is recognition that our unique, fruitfly-based approach to SMA research offers the potential for a novel treatment for this lethal disease. This is VASTox’s first charitable grant and we will work closely with the AFM and other like-minded charities to accelerate our drug discovery efforts wherever possible."

Arizona Biotech Wins Blog of the Day Award

Arizona Biotech Wins Blog of the Day Award

Weblog Awards



Biotech News

Friday, November 10, 2006

Growth and Leadership Are Top Priorities for the End of the Decade, Monsanto MON Executives Tell European Investors

Growth and Leadership Are Top Priorities for the End of the Decade, Monsanto Executives Tell European Investors


Monsanto (NYSE: MON) has a unique window of opportunity to build on its industry leading position and capitalize on emerging growth opportunities between now and the end of the decade, company executives told investors today.

The company's remarks came as part of an investor meeting held in London, which featured presentations by Hugh Grant, chairman, president and chief executive officer; Robb Fraley, executive vice president and chief technology officer; and Terry Crews, executive vice president and chief financial officer.

At the event, Monsanto's management team outlined key factors expected to drive the company's growth through 2010 and confirmed its earnings per share (EPS) and free cash flow guidance for fiscal-year 2007.

"The leadership we enjoy today is not accidental," said Grant. "It represents our strategic decision to orient our business around our seeds and traits platform, and then passionately execute against that strategy literally farm-by-farm and field-by-field.

"While our early investment gave us a head start, it is our performance -- backed by the industry's leading R&D pipeline, and coupled with our principles of relentless innovation, commercial execution and delivery against our commitments -- that will help us build on our leadership in the years ahead," said Grant.

Growth Contributors Expected To Expand Window of Leadership, Deliver Greater Profitability

Monsanto's management team has identified six elements which will contribute to the growth of the company's seeds and traits business between now and 2010. These include: its U.S. and ex-U.S. corn seeds and traits business; its international traits business; its cotton business; its Seminis fruit and vegetable seed business; and its R&D pipeline.

By executing its strategy against these six contributors, Monsanto will not only be able to deliver value to its farmer customers, but expects to grow the profitability of the business, increasing gross profit as a percent of sales from 48 percent today, to a target of 51 to 53 percent by the end of the decade, Grant said.

In outlining the six factors that would drive the company's gross-profit growth through the end of the decade, Monsanto's management team highlighted a number of opportunities and new developments, including:

-- Monsanto's U.S. corn seed and trait market continues to serve as a
centerpiece of growth. With the continued market share growth of
Monsanto's national DEKALB and Asgrow corn seed brands and increased
adoption of Monsanto biotech traits, the U.S. corn market is a margin-
rich business with opportunity for expansion. Notably, Monsanto
continues to expect that its national seed brands can continue to grow
at the rate of 1 to 2 share points per year through the end of the
decade. The company projects a potential U.S. trait market of
approximately 150 million trait acres, which creates the opportunity
to effectively double trait penetration by 2010.

-- Monsanto's breeding pipeline is developing better seed that outyields
competitive offerings. Preliminary harvest results from 2006 testing
indicated that Monsanto's DEKALB branded seed corn demonstrated an 11-
bushel-acre yield advantage when compared with competitive offerings.
The preliminary results, which were realized in the 110-day relative
maturity planting zone, highlight the benefit that Monsanto's seed
products are delivering to farmers in the Central Corn Belt, an area
which generates more than one-third of the nation's grain production.

-- The R&D pipeline is set to deliver further value, reflected in a new
listing of "Top 10" projects. Complementing the "High-Impact
Technologies" (HITs) the company established in fiscal year 2006,
Monsanto unveiled a top-10 listing of products in its R&D pipeline,
reflecting the products in development that are poised to deliver the
most value based on factors such as crop size, market need, uniqueness
of the technology, and the ability to establish new platforms for
future traits.

-- R&D "HIT" projects are on track and have the company geared up for
larger-acre launches with greater financial benefit to the company.
The progress of the HIT projects is reinforced by 2006 testing, where
Monsanto tested its Roundup RReady2Yield soybean technology with more
than 45 trials, spanning 25 locations on more than 11,000 lines.
During 2006, the company also conducted more than 85,000 drought test
plots to better assess its drought-tolerant technology and its
benefits for corn, cotton and soybean farmers.

-- The tools of molecular breeding will be able to improve the Seminis
vegetable seed platform and its offerings. Using the technology and
tools that were first applied to Monsanto's core row crop business,
scientists are actively developing genetic maps and molecular markers
for nine key vegetable crops. With the ongoing work, Monsanto expects
to develop approximately 1,000 molecular markers for each crop by the
end of the decade -- or a total of 9,000 markers that can be used for
advanced breeding.

-- The strong business performance, underpinned by financial discipline,
creates a platform for growth and a greater opportunity to return
value to shareowners. In the past three fiscal years, Monsanto
returned three-quarters of free cash generated to shareowners, either
directly through share repurchases and dividends, or by re-investing
in the growth of the business.


Company Reiterates Guidance for Fiscal Year 2007

In the final presentation of the day, Crews reviewed the company's key financial projections. He underscored the opportunity created by a company uniquely positioned for leadership in the seeds-and-traits segment of the agricultural industry.

Crews noted that the company continues to expect that its full-year 2007 EPS guidance, both on a reported and ongoing basis, is expected to be in the range of $1.50 to $1.57. (For a reconciliation of ongoing EPS, see note 1.)

"At Monsanto, guidance is a commitment, not an aspiration," said Crews. "Our projected 15 to 20 percent growth rate for ongoing EPS in 2007 reflects our confidence in the substantial organic growth potential of our seeds and traits, even in a dynamic agricultural market.

"If we accomplish our objectives over the mid-term, we have a unique window of opportunity to extend our leadership and reward our shareowners for their investment in our company."

Crews also underscored that the company still expects guidance for free cash flow for fiscal year 2007 will be in the range of $875 million to $950 million. The company expects net cash provided by operating activities to be in the range of $1.3 billion to $1.4 billion, and net cash required by investing activities to be approximately $500 million for fiscal year 2007. (For a reconciliation of free cash flow, see note 1.)

2006 European Investor Meeting Background

A live webcast of Monsanto's European investor briefing will be available through Monsanto's web site beginning at 3 a.m. Central Standard Time this morning, Friday, Nov. 10, 2006. This webcast is available at: http://www.monsanto.com/monsanto/layout/investor/financial/presentations.asp . Following the live broadcast, a replay of the webcast will be available on the Monsanto web site for two weeks.

Materials related to this investor briefing, including: the presentation agenda, briefing slides, transcripts, and speaker bios will also be available through Monsanto's web site at: http://www.monsanto.com/monsanto/layout/featured/europe_conference/default.asp . To access presentation slides and the simultaneous audio webcast of the presentation, visitors may need to download Windows Media Player(TM) prior to listening to the webcast.

Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality.

Cautionary Statements Regarding Forward-Looking Information:

Certain statements contained in this release are "forward-looking statements," such as statements concerning the company's anticipated financial results, current and future product performance, regulatory approvals, business and financial plans and other non-historical facts. These statements are based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company's actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: continued competition in seeds, traits and agricultural chemicals; the company's exposure to various contingencies, including those related to intellectual property protection, regulatory compliance and the speed with which approvals are received, and public acceptance of biotechnology products; the success of the company's research and development activities; the outcomes of major lawsuits, including proceedings related to Solutia Inc.; developments related to foreign currencies and economies; successful completion and operation of recent and proposed acquisitions, including Delta and Pine Land Company; fluctuations in commodity prices; compliance with regulations affecting our manufacturing; the accuracy of the company's estimates related to distribution inventory levels; the company's ability to fund its short-term financing needs and to obtain payment for the products that it sells; the effect of weather conditions, natural disasters and accidents on the agriculture business or the company's facilities; and other risks and factors detailed in the company's filings with the SEC. Undue reliance should not be placed on these forward-looking statements, which are current only as of the date of this release. The company disclaims any current intention or obligation to update any forward-looking statements or any of the factors that may affect actual results.

Notes to editors: DEKALB, Asgrow and Roundup RReady2Yield are trademarks of Monsanto Company and its wholly owned subsidiaries.

Monsanto Company
Selected Financial Information
(Dollars in millions)
Unaudited

1. Ongoing EPS and Free Cash Flow: The presentations of ongoing EPS and
free cash flow are not intended to replace net income (loss), cash
flows, financial position or comprehensive income (loss), and they are
not measures of financial performance as determined in accordance with
generally accepted accounting principles (GAAP) in the United States.
The following tables reconcile EBIT, ongoing EPS and free cash flow to
the respective most directly comparable financial measure calculated
in accordance with GAAP.

Reconciliation of EPS to Ongoing EPS: Ongoing EPS is calculated
excluding certain after-tax items which Monsanto does not consider
part of ongoing operations.



Fiscal Year Fiscal Fiscal
2007 Year Year
Target 2006 2005
Diluted Earnings per Share $1.50 - $1.57 $1.25 $0.47
Tax Charge on Repatriated Earnings - 0.04 -
Loss (Income) on Discontinued
Operations - 0.01 (0.02)
Cumulative Effect of Change in
Accounting Principle - 0.01 -
Solutia-Related Charge - - 0.32
Tax Benefit on Loss from European
Wheat and Barley Business - - (0.19)
Restructuring Charges - Net - - 0.01
Seminis & Stoneville In-Process R&D - - 0.45
Diluted Earnings per Share from
Ongoing Business $1.50 - $1.57 $1.31 $1.04


Reconciliation of Free Cash Flow: Free cash flow represents the total
of cash flows from operating activities and investing activities, as
reflected in the Statements of Consolidated Cash Flows. With respect
to the fiscal year 2007 free cash flow target, Monsanto does not
include any estimates or projections of Net Cash Provided (Required)
by Financing Activities because in order to prepare any such estimate
or projection, Monsanto would need to rely on market factors and
conditions that are outside of its control.




Fiscal Year 12 Months Ended
2007 Aug. 31,
Target 2006 2005
Net Cash Provided by Operating
Activities $1,375 - $1,450 $1,674 $1,737
Net Cash Required by Investing
Activities (500) (625) (1,667)
Free Cash Flow $875 - $950 $1,049 $70
Net Cash Required by Financing
Activities N/A (117) (582)
Effect of Exchange Rate Changes
on Cash and Cash Equivalents N/A 3 -
Net Increase (Decrease) in Cash
and Cash Equivalents N/A $935 $(512)
Cash and Cash Equivalents at
Beginning of Period N/A $525 $1,037
Cash and Cash Equivalents at End
of Period N/A $1,460 $525

Cardinal Health CAH Names Mark Parrish CEO of Healthcare Supply Chain Services




Cardinal Health, the leading provider of products and services supporting the health-care industry, announced today that Mark Parrish has been named chief executive officer of the company's $77-billion Healthcare Supply Chain Services sector, reporting to President and CEO R. Kerry Clark.

Parrish, 51, previously was the group president of Healthcare Supply Chain Services' Pharmaceutical segment. In his new role, which is effective immediately, Parrish is responsible for all of Cardinal Health's supply chain units, which comprise the nation's largest provider of pharmaceuticals, medical equipment, and supplies. The company's customers include retail and independent pharmacies, hospitals, laboratories, and physician offices.

"We conducted an extensive internal and external candidate search for this critical position and we are pleased to promote the best candidate from within the company," Clark said. "The board and I unanimously agreed that Mark has what we and the industry need to bring progressive supply chain practices to health care."

Cardinal Health has embarked on an ambitious strategy to integrate its supply chain operations along with a broad range of related logistics services that improve the delivery and economics of health care.

Healthcare Supply Chain Services is Cardinal Health's largest business, distributing products from 3,000 manufacturers of pharmaceuticals, medical supplies and equipment to pharmacies, hospitals, clinics, and lab customers every day. In fiscal 2006, the company reported nearly $70 billion in revenue from pharmaceutical supply chain services and $7.2 billion in revenue from medical supply chain services.

"We have a truly unique opportunity to bring to the industry a systematic approach to the management of pharmaceuticals and supplies," Mark Parrish said. "We have the potential to meaningfully improve economics for our suppliers and customers, while helping them achieve other goals associated with patient and practitioner safety and satisfaction."

Parrish's career in health care spans nearly 25 years. Last month he was elected chairman of the Healthcare Distribution Management Association.

Mark Parrish joined Cardinal Health in 1993. Since 2003, he led Cardinal Health's pharmaceutical distribution businesses, including all of its offerings for retailers, mail-order firms, long-term care and hospital pharmacies, pharmacy-franchising operations, specialized blood-product distribution, and logistics services for pharmaceutical and biotech firms. Before this, Parrish held several leadership positions in Cardinal Health's pharmaceutical distribution and pharmacy-franchising units. He joined Cardinal Health after positions of increasing leadership at Foxmeyer Health Corp., General Medical Corp., Bergen Brunswig Corp., and Procter & Gamble. He holds a bachelor's degree from the University of California, Berkeley.

Parrish fills the position held by Ronald K. Labrum, who left Cardinal Health in September.

About Cardinal Health

Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is an $81 billion, global company serving the health-care industry with a broad portfolio of products and services. It manufactures, packages, and distributes pharmaceuticals and medical supplies, offers a range of clinical services and develops automation products that improve the management and delivery of supplies and medication for hospitals, physician offices and pharmacies. Through this diverse offering, Cardinal Health delivers integrated health-care solutions that help customers reduce their costs, improve efficiency and deliver better care to patients. Ranked No. 19 on the Fortune 500, Cardinal Health employs more than 55,000 people on six continents. More information about the company may be found at http://www.cardinalhealth.com/.

Except for historical information, all other information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward- looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: competitive pressures in its various lines of business; the loss of one or more key customer or supplier relationships or changes to the terms of those relationships; changes in the distribution patterns or reimbursement rates for health-care products and/or services; the results, consequences, effects or timing of any inquiry or investigation by or settlement discussions with any regulatory authority or any legal and administrative proceedings, including shareholder litigation; difficulties in opening new facilities or fully utilizing existing capacity; the costs, difficulties and uncertainties related to the integration of acquired businesses; and general economic and market conditions. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement.

Biotech News - Biosite Incorporated (Public, NASDAQ:BSTE)

Biosite Incorporated (Public, NASDAQ:BSTE)

Biosite Incorporated Reports New Option Grants Under NASDAQ
Marketplace Rule 4350
Wednesday November 1, 4:02 pm ET

SAN DIEGO, Nov. 1 Biosite® Incorporated (Nasdaq: BSTE - News), today
announced that, in accordance with NASDAQ Marketplace Rule 4350, 45
non-officer employees were granted inducement stock options covering
an aggregate of 69,900 shares of common stock. These options were
granted pursuant to NASDAQ Marketplace Rule 4350 (i)(1)(A)(iv) with
the following terms: each option has been classified as a non-
qualified stock option, has an exercise price equal to the fair
market value on the grant date, has a ten-year term, and vests in 16
equal quarterly installments over four years (on each quarterly
anniversary of the applicable vesting commencement date).




About Biosite Incorporated

Biosite Incorporated is a leading bio-medical company
commercializing proteomics discoveries for the advancement of
medical diagnosis. The Company's products contribute to improvements
in medical care by aiding physicians in the diagnosis of critical
diseases and health conditions. Biosite's Triage® rapid diagnostics
are used in more than 50 percent of U.S. hospitals and in more than
50 international markets. Information on Biosite can be found at
www.biosite.com.

Biosite® Triage® and New Dimensions in Diagnosis® are registered
trademarks of Biosite Incorporated. The Company's logo is a
trademark of Biosite Incorporated.

Source: Biosite Incorporated

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - ImClone Systems Incorporated (Public, NASDAQ:IMCL)

ImClone Systems Incorporated (Public, NASDAQ:IMCL)

Survival Data Available from Two Randomized ERBITUX Studies in
Metastatic Colorectal Cancer

- NCIC CTG study meets primary endpoint by significantly improving
overall survival -
- EPIC secondary endpoints strongly favor ERBITUX combination;
primary endpoint not met possibly due to post-study therapy -

NEW YORK, Nov. 6 ImClone Systems Incorporated (Nasdaq: IMCL - News)
and Bristol-Myers Squibb Company (NYSE: BMY - News) today announced
results from two randomized Phase III trials of ERBITUX® (cetuximab)
in patients with metastatic colorectal cancer. These are the first
large, randomized studies to examine the impact of ERBITUX treatment
on overall survival in colon cancer.



A randomized, multicenter, Phase III trial (NCIC CTG CO.17) compared
ERBITUX plus best supportive care to best supportive care alone in
572 patients with metastatic colorectal cancer whose disease was
refractory to all available chemotherapy, including irinotecan,
oxaliplatin, and fluoropyrimidines. The study, conducted by the
National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)
in collaboration with the Australasian Gastro-Intestinal Trials
Group (AGITG), met its primary efficacy endpoint showing a
statistically significant improvement in overall survival. These are
the first data of an anticancer therapy to demonstrate overall
survival in this refractory treatment setting. The NCIC CTG is
scheduled to submit the data from this study for presentation at a
major medical meeting in 2007.

"This is the second tumor type where ERBITUX has shown survival
benefit," said Eric Rowinsky, M.D., Chief Medical Officer and Senior
Vice President of ImClone Systems. "Additionally, no other EGFR-
targeted therapy has demonstrated an improvement in overall survival
in a Phase III colorectal cancer clinical study."

A second Phase III, randomized study, known as the Erbitux Plus
Irinotecan in Colorectal Cancer (EPIC), compared irinotecan to
irinotecan plus ERBITUX in approximately 1,300 patients whose
disease was not responding to first-line oxaliplatin-based
chemotherapy. After randomization, patients were treated until their
disease progressed. Upon disease progression, study treatment was
stopped and further treatment was at the discretion of the physician.

Secondary efficacy endpoints (progression free survival, response
rate) strongly favored the combination of ERBITUX plus irinotecan
over irinotecan alone; however, the primary endpoint (overall
survival) was not met.

Efforts to interpret these confounded results are ongoing. A
preliminary review of the data reveal that a considerable number of
patients randomized to the irinotecan arm went on to receive ERBITUX
with or without irinotecan after failing irinotecan alone.

"The studies provide important new information for patients with
advanced colorectal cancer, and are part of our comprehensive
clinical development program designed to fully understand the
potential uses of ERBITUX for cancer patients," said Martin
Birkhofer, M.D., Vice President, Oncology Global Medical Affairs,
Bristol-Myers Squibb. "We look forward to our full analysis of the
data, and to sharing the results with the scientific community at a
major medical meeting."

"We are encouraged by the totality of the results from both studies
and we plan to have discussions with the Food and Drug
Administration concerning a registrational submission," said Eric
Rowinsky, M.D. Chief Medical Officer and Senior Vice President of
ImClone Systems.

About ERBITUX® (Cetuximab)

ERBITUX is a monoclonal antibody (IgG1 Mab) designed to inhibit the
function of a molecular structure expressed on the surface of normal
and tumor cells called the epidermal growth factor receptor (EGFR,
HER1, c-ErbB-1). In vitro assays and in vivo animal studies have
shown that binding of ERBITUX to the EGFR blocks phosphorylation and
activation of receptor-associated kinases, resulting in inhibition
of cell growth, induction of apoptosis, and decreased matrix
metalloproteinase and vascular endothelial growth factor production.
In vitro, ERBITUX can mediate antibody-dependent cellular
cytotoxicity (ADCC) against certain human tumor types. While the
mechanism of ERBITUX' anti-tumor effect(s) in vivo is unknown, all
of these processes may contribute to the overall therapeutic effect
of ERBITUX. EGFR is part of a signaling pathway that is linked to
the growth and development of many human cancers, including those of
the head and neck, colon and rectum.

ERBITUX (Cetuximab), in combination with radiation therapy, is
indicated for the treatment of locally or regionally advanced
squamous cell carcinoma of the head and neck. ERBITUX as a single
agent is indicated for the treatment of patients with recurrent or
metastatic squamous cell carcinoma of the head and neck for whom
prior platinum-based therapy has failed.

ERBITUX is indicated for the treatment of EGFR-expressing,
metastatic colorectal carcinoma (mCRC) in combination with
irinotecan for patients who are refractory to irinotecan-based
chemotherapy, and as a single agent for patients who are intolerant
to irinotecan-based therapy. The effectiveness of ERBITUX for the
treatment of EGFR-expressing mCRC cancer is based on objective
response rates. Currently, no data are available that demonstrate an
improvement in disease-related symptoms or increased survival with
ERBITUX for the treatment of EGFR-expressing mCRC.

For full prescribing information, including boxed WARNINGS regarding
infusion reactions and cardiopulmonary arrest, visit
http://www.ERBITUX.com

Important Safety Information

Grade 3/4 infusion reactions, rarely with fatal outcome (<1 in
1000), occurred in approximately 3% (46/1485) of patients receiving
ERBITUX (Cetuximab) therapy. These reactions are characterized by
rapid onset of airway obstruction (bronchospasm, stridor,
hoarseness), urticaria, hypotension, and/or cardiac arrest. Severe
infusion reactions require immediate and permanent discontinuation
of ERBITUX therapy.

Most reactions (90%) were associated with the first infusion of
ERBITUX despite the use of prophylactic antihistamines. Caution must
be exercised with every ERBITUX infusion as there were patients who
experienced their first severe infusion reaction during later
infusions. A 1-hour observation period is recommended following the
ERBITUX infusion. Longer observation periods may be required in
patients who experience infusion reactions.

Cardiopulmonary arrest and/or sudden death occurred in 2% (4/208) of
patients with squamous cell carcinoma of the head and neck treated
with radiation therapy and ERBITUX as compared to none of 212
patients treated with radiation therapy alone. Fatal events occurred
within 1 to 43 days after the last ERBITUX treatment. ERBITUX in
combination with radiation therapy should be used with caution in
patients with known coronary artery disease, congestive heart
failure and arrhythmias. Close monitoring of serum electrolytes,
including serum magnesium, potassium, and calcium during and after
ERBITUX therapy is recommended.

Severe cases of interstitial lung disease (ILD), which was fatal in
one case, occurred in less than 0.5% of 774 patients with advanced
colorectal cancer (mCRC) receiving ERBITUX. There was one case of
ILD reported in 796 patients with head and neck cancer receiving
ERBITUX in clinical studies.

In clinical studies of ERBITUX, dermatologic toxicities, including
acneform rash, skin drying and fissuring, and inflammatory and
infectious sequelae (eg, blepharitis, cheilitis, cellulitis, cyst)
were reported. In 208 patients receiving ERBITUX + RT, acneform rash
was reported in 87% (17% severe) as compared to 10% in 212 patients
treated with radiation therapy alone (1% severe). In patients
receiving ERBITUX alone, 76% (N=103) experienced acneform rash (1%
severe). In patients with mCRC, acneform rash was reported in 89%
(686/774) of all treated patients, and was severe in 11% (84/774).
Subsequent to the development of severe dermatologic toxicities,
complications including S. aureus sepsis and abscesses requiring
incision and drainage were reported. Sun exposure may exacerbate
these effects. A related nail disorder, occurring in 12% (0.4% Grade
3) of patients, was characterized as a paronychial inflammation.

The safety of ERBITUX in combination with radiation therapy and
cisplatin has not been established. Death and serious cardiotoxicity
were observed in a single-am trial with ERBITUX, delayed,
accelerated (concomitant boost) fractionation radiation therapy, and
cisplatin (100 mg/m2) conducted in patients with locally advanced
squamous cell carcinoma of the head and neck. Two of 21 patients
died, one as a result of pneumonia and one of an unknown cause. Four
patients discontinued treatment due to adverse events. Two of these
discontinuations were due to cardiac events (myocardial infarction
in one patient and arrhythmia, diminished cardiac output, and
hypotension in the other patient).

The incidence of hypomagnesemia (both overall and severe [NCI CTC
Grades 3 & 4]) was increased in patients receiving ERBITUX alone or
in combination with chemotherapy as compared to those receiving best
supportive care or chemotherapy alone based on ongoing, controlled
clinical trials in 244 patients. Approximately one-half of these
patients receiving ERBITUX experienced hypomagnesemia and 10-15%
experienced severe hypomagnesemia. Electrolyte repletion was
necessary in some patients and in severe cases, intravenous
replacement was required. Patients receiving ERBITUX therapy should
be periodically monitored for hypomagnesemia, and accompanying
hypocalcemia and hypokalemia during, and up to 8 weeks following the
completion of, ERBITUX therapy.

The most serious adverse reactions associated with ERBITUX in
combination with radiation therapy in 208 patients with head and
neck cancer were infusion reaction (3%), cardiopulmonary arrest
(2%), dermatologic toxicity (2.5%), mucositis (6%), radiation
dermatitis (3%), confusion (2%), and diarrhea (2%).

The most serious adverse reactions associated with ERBITUX in mCRC
clinical trials (N=774) were infusion reaction (3%), dermatologic
toxicity (1%), interstitial lung disease (0.4%), fever (5%), sepsis
(3%), kidney failure (2%), pulmonary embolus (1%), dehydration (5%
in patients receiving ERBITUX with irinotecan, 2% in patients
receiving ERBITUX as a single agent) and diarrhea (6% in patients
receiving ERBITUX with irinotecan, 0.2% in patients receiving
ERBITUX as a single agent).

The overall incidence of late radiation toxicities (any grade) was
higher with ERBITUX in combination with radiation therapy compared
with radiation therapy alone. The following sites were affected:
salivary glands (65%/56%), larynx (52%/36%), subcutaneous tissue
(49%/45%), mucous membranes (48%/39%), esophagus (44%/35%), skin
(42%/33%), brain (11%/9%), lung (11%/8%), spinal cord (4%/3%), and
bone (4%/5%) in the ERBITUX and radiation versus radiation alone
arms, respectively.

The incidence of Grade 3 or 4 late radiation toxicities were
generally similar between the radiation therapy alone and the
ERBITUX plus radiation therapy arms.

The most common adverse events seen in patients with carcinomas of
the head and neck receiving ERBITUX in combination with radiation
therapy (n=208) versus radiation alone (n=212) were mucositis-
stomatitis (93%/94%), acneform rash (87%/10%), radiation dermatitis
(86%/90%), weight loss (84%/72%), xerostomia (72%/71%), dysphagia
(65%/63%), asthenia (56%/49%), nausea (49%/37%), constipation
(35%/30%) and vomiting (29%/23%). The most common adverse events
seen in patients with carcinomas of the head and neck receiving
ERBITUX as a single agent (N=103) were acneform rash (76%), asthenia
(45%), pain (28%), fever (27%) and weight loss (27%).

The most common adverse events seen in patients with mCRC receiving
ERBITUX with irinotecan (n=354) or ERBITUX as a single agent (n=420)
were acneform rash (88%/90%), asthenia/malaise (73%/48%), diarrhea
(72%/25%), nausea (55%/29%), abdominal pain (45%/26%), vomiting
(41%/25%), fever (34%/27%), constipation (30%/26%), and headache
(14%/26%).

About Colorectal Cancer

In the U.S., approximately 149,000 people will be diagnosed with
cancer of the colon or rectum this year. Half of these patients have
metastatic disease, or cancer that has spread to other organs, at
the time of diagnosis. EGFR is expressed in up to 77.7 % of
colorectal cancer tumors. Colorectal cancer is the third most common
cancer in both men and women.(1)

About ImClone Systems

ImClone Systems Incorporated is committed to advancing oncology care
by developing a portfolio of targeted biologic treatments designed
to address the medical needs of patients with a variety of cancers.
The Company's research and development programs include growth
factor blockers and angiogenesis inhibitors. ImClone Systems'
strategy is to become a fully integrated biopharmaceutical company,
taking its development programs from the research stage to the
market. ImClone Systems' headquarters and research operations are
located in New York City, with additional administration and
manufacturing facilities in Branchburg, New Jersey.

Certain matters discussed in this news release may constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 and the Federal securities
laws. Although the company believes that the expectations reflected
in such forward-looking statements are based upon reasonable
assumptions it can give no assurance that its expectations will be
achieved. Forward-looking information is subject to certain risks,
trends and uncertainties that could cause actual results to differ
materially from those projected. Many of these factors are beyond
the company's ability to control or predict. Important factors that
may cause actual results to differ materially and could impact the
company and the statements contained in this news release can be
found in the company's filings with the Securities and Exchange
Commission, including quarterly reports on Form 10-Q, current
reports on Form 8-K and annual reports on Form 10-K. For forward-
looking statements in this news release, the company claims the
protection of the safe harbor for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995.
The company assumes no obligation to update or supplement any
forward-looking statements whether as a result of new information,
future events or otherwise.

About Bristol-Myers Squibb

Bristol-Myers Squibb is dedicated to the discovery, development and
exhaustive exploration of innovative cancer fighting therapies
designed to extend and enhance the lives of patients living with
cancer. More than 40 years ago, Bristol-Myers Squibb built a unified
vision for the future of cancer treatment. With expertise,
dedication and resolve, that vision led to the development of a
diverse global portfolio of anti-cancer therapies that are an
important cornerstone of care today. Hundreds of scientists at
Bristol-Myers Squibb's Pharmaceutical Research Institute are
studying ways to improve current cancer treatments and identify
better, more effective medicines for the future.

Bristol-Myers Squibb is a global pharmaceutical and related health
care products company whose mission is to extend and enhance human
life.

This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding product development. Such forward-looking statements
are based on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. There can be no guarantee that a registrational
submission will me made to the FDA based on the data described in
this press release or if such registrational submission is made,
that it would receive FDA approval. Forward-looking statements in
this press release should be evaluated together with the many
uncertainties that affect Bristol- Myers Squibb's business,
particularly those identified in the cautionary factors discussion
in Bristol-Myers Squibb's Annual Report on Form 10-K for the year
ended December 31, 2005 and in our Quarterly Reports on Form 10-Q.
Bristol-Myers Squibb undertakes no obligation to publicly update any
forward- looking statement, whether as a result of new information,
future events or otherwise.

(1) American Cancer Society: Cancer Facts and Figures 2006.

http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf.

Source: Bristol-Myers Squibb Company

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Human Genome Sciences (Public, NASDAQ:HGSI)

Human Genome Sciences (Public, NASDAQ:HGSI)

Human Genome Sciences to Sponsor Conference Call to Discuss Third
Quarter 2006 Financial Results

Human Genome Sciences,
Inc. (Nasdaq: HGSI) announced that it will sponsor a conference call
to discuss its financial results for the quarter ended September 30,
2006.
These results are expected to be disclosed on Wednesday, November 8,
2006, before the capital markets open.

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Myogen, Inc. (Public, NASDAQ:MYOG)

Myogen, Inc. (Public, NASDAQ:MYOG)

J. William Freytag, Ph.D., President & CEO of Myogen to Be Special
Guest at 14th Annual Biotech Investing Conference

NEW YORK, NY -- October 26, 2006 -- IBF Conferences, Inc. and SRI
International today announced that J. William Freytag, Ph.D.,
President & CEO of Myogen, will be a special guest at the 14th
Annual Biotech Investing Conference held at SRI International at
Menlo Park, CA.

Mr. Freytag will be the special guest during the fireside chat to be
held on November 8th at 4:30 PM. Camille Samuels, Managing Director
of Versant Ventures, will be conducting the interview and said of
Mr. Freytag, "Bill has been at the helm of Myogen since 1998 -- and
successfully led the company through many of biotech's toughest
challenges including fundraising in difficult times and managing
through a product failure. Now, Bill is preparing to transition
Myogen to its acquirer, Gilead, for $2.5 Billion! Every student of
biotechnology can learn from Bill's experiences and thoughtful
approach."


The 14th Annual Biotech Investing Conference, November 8, 2006,
being held at SRI International, is a program to keep venture
investors informed of emerging trends in the biotech sector, as well
as investing strategies and collaborative business opportunities. In
addition, the conference will also provide big pharma's perspective
on rebuilding the pipeline and a look at how foundations are
becoming a tool to fund early-stage research. There will also be an
NVCA hosted pre conference reception held on November 7th --
CELEBRATE THE EMERGENCE OF A NEW CLASS OF BIOTECH INVESTORS -- which
is free for all to attend.

Join leading firms such as New Enterprise Associates, Versant
Ventures, CMEA Ventures and Amgen Ventures as well as foundations
such as The Michael J. Fox Foundation for Parkinson's Research and
Cystic Fibrosis Foundation Therapeutics, along with the FDA to
discuss the following topics:

-- TRENDS IN EARLY, MID AND LATER STAGE BIOMEDICAL INVESTING
-- PRIVATE EQUITY INVESTOR & HEDGE FUND APPETITE FOR BIO COMPANIES
-- FOUNDATIONS "BRIDGE THE GAP": PARTNERING WITH VCS AND
ENTREPRENEURS
TO FUND EARLY STAGE BIOTECH
-- BIG PHARMA SPEAKS OUT ON THEIR APPROACH TO FILLING THEIR PIPELINE
-- FDA ACCELERATED DRUG DEVELOPMENT PROGRAMS:
- KEY ISSUES IN ADDRESSING ORPHAN MARKETS
- HOW THE FDA IS SUPPORTING ACCELERATED DRUG DEVELOPMENT
-- EXIT OUTLOOK

This year's conference sponsors include: SRI International, ABD
Insurance & Financial Services, GE Healthcare Financial Services
Life Science Finance, O'Melveny & Myers LLP and Charter Life
Sciences.

SOURCE: IBF Conferences Inc.

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Thursday, November 09, 2006

Biotech News - Bodisen Biotech, Inc. (Public, AMEX:BBC)

Bodisen Biotech, Inc. (Public, AMEX:BBC)

Bodisen Biotech, Inc. to Report Third Quarter 2006 Financial Results
On November 15, 2006

Bodisen Biotech, Inc. (AMEX:BBC) (website: www.bodisen.com)
announced today that it will report its financial results for the
third quarter ended September 30, 2006 on Wednesday, November 15,
2006.


The management team will also host its earnings conference call on
the same day at 5:00 pm Eastern Time. Bodisen Chairwoman and Chief
Executive Officer Karen Qiong Wang and President Bo Chen will be on
the call to discuss the quarterly results and highlights, and to
answer questions.

The conference call will be available on webcast live at
www.bodisen.com and available for replay at the company's corporate
web site for 90 days. A replay of the call will be available by
dialing 800-405-2236 (international 303-590-3000), and entering
passcode 11074999#. The replay will be available starting at 8PM EST
on November 15, 2006 and through 5PM EST November 22, 2006.

About Bodisen Biotech, Inc.

Bodisen Biotech Inc. (AMEX:BBC) is a leading manufacturer of liquid
and organic compound fertilizers, pesticides, insecticides and
agricultural raw materials certified by the Petroleum Chemical
Industry Administrative office of China (Chemical Petroleum
Production Administrative Bureau), Shaanxi provincial government and
Chinese government. Ranked the 16th fastest growing company in China
by Forbes China in January 2006, the company is headquartered in
Shaanxi province and is a Delaware corporation. The company's
environmentally friendly "green" products have been proven to
improve soil and plant quality, and increase crop yields.

Safe Harbor Statement

This press release may contain forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based on the
current expectations or beliefs of Bodisen Biotech, Inc. management
and are subject to a number of factors and uncertainties that could
cause changes to the planned earnings conference call from the
description in the forward-looking statements.

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Forest Laboratories, Inc. (Public, NYSE:FRX)

Forest Laboratories, Inc. (Public, NYSE:FRX)

Forest Laboratories recruitment to resume in stroke trial
Forest Laboratories Inc. (FRX) plans to resume patient enrollment in
its DIAS-2 Phase IIb/III desmoteplase study after an independent data
monitoring committee reviewed data concerning a potential safety
signal.

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Hospira, Inc. (Public, NYSE:HSP)

Hospira, Inc. (Public, NYSE:HSP)

George Soros sold out his holdings in Pharmaceuticals operator
Hospira Inc.(HSP) during the 3-months ended 2006-06-30. His sale
prices were between $ 36.95

Press Release Source: Hospira, Inc.

Hospira Expands Board of Directors
Tuesday October 31, 11:00 am ET

Hospira, Inc. (NYSE: HSP - News), a leading global hospital products
company, announced that Roger W. Hale, retired chairman and chief
executive officer of LG&E Energy Corporation, has been elected to
the company's board of directors. The addition of Hale expands
Hospira's board to nine directors, of whom eight are independent.


"We welcome Roger's expertise in leading and advising companies,"
said David A. Jones, chairman, Hospira. "His experience successfully
guiding organizations through change and building corporations that
deliver long-term growth will be a valuable addition to our board."

Hale, 63, was chairman of the board and chief executive officer of
LG&E Energy, a diversified energy services company, from 1989 until
his retirement in 2001. He led LG&E Energy through numerous
expansions, including the formation of LG&E Energy Corporation as
the holding company for Louisville Gas & Electric Company and
subsequently its merger with Kentucky Utilities Company. He also
broadened the company's scope internationally through acquisitions
and joint ventures.

Hale has held leadership positions in the telecommunications
industry, including his role as former executive vice president of
BellSouth Corporation, and executive positions with AT&T Co.,
including vice president, Southern Region. Hale currently serves on
the boards of Ashland, Inc., a global chemical company; and H&R
Block, Inc., a leading provider of tax, financial, mortgage,
accounting, and business consulting services and products. He
received a bachelor's degree from the University of Maryland and a
master's degree from the Massachusetts Institute of Technology Sloan
School of Management.

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Celgene Corporation NASDAQ:CELG & Gilead Sciences, Inc. Nasdaq:GILD

Celgene Corporation (Public, NASDAQ:CELG)

Gilead Sciences Completes Acquisition of Raylo Chemicals Inc. and
Celgene Announces Pricing of Common Stock Offering

Biotechnology industry news Gilead Sciences, Inc. (Nasdaq:GILD)
recently announced that the company has completed its acquisition of
Raylo Chemicals Inc., a subsidiary of Germany-based specialty
chemicals company Degussa AG, for approximately 107 million euros.
Gilead intends to utilize this Edmonton, Alberta-based site for
process research and scale-up of clinical development candidates,
for manufacturing of active pharmaceutical ingredients (API) for
both investigational and commercial products and for chemical
development activities to improve existing commercial manufacturing
processes. PDL BioPharma Inc. (Nasdaq:PDLI) said Thursday it posted
a narrower third-quarter loss as revenue jumped 44 percent in large
part on gains from a severed collaboration with Roche. The company
lost $6.7 million, or 6 cents per share, compared with a loss of
$45.2 million, or 43 cents per share, a year ago. Analysts polled by
Thomson Financial expected a loss of 1-cent per share.

Celgene Corporation (Nasdaq: CELG), announced the pricing of its
public offering of 20,000,000 shares of its common stock at a public
offering price of $51.60 per share. The gross proceeds of the
offering will be $1.032 billion. This offering of the shares of
Celgene common stock may be made only by means of a prospectus.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company. NutraCea, (OTC BB:
NTRZ) the world leader in stabilized rice bran technology, is
pleased to announce that its Chief Executive Officer, Mr. Brad
Edson, is scheduled to present at the Rodman & Renshaw 8th Annual
Healthcare Conference on November 6, 2006 at 9:10 a.m. EST. The
three-day conference is being held at the New York Palace in New
York City and will include presentations by over 300 companies, as
well as experts from the medical, scientific and investment
communities.

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Cardinal Health, Inc. (Public, NYSE:CAH)

Cardinal Health, Inc. (Public, NYSE:CAH)

DuPont reaches settlement with Cardinal Health
Business First of Columbus - October 30, 2006
Print this Article Email this Article Reprints RSS Feeds Most Viewed
Most Emailed
Chemicals giant E.I. DuPont De Nemours & Co. said Monday it has
reached a settlement with Cardinal Health Inc. to resolve
allegations of breach of contract brought against the Dublin health-
care company.

DuPont filed suit against Cardinal in 2003 over the production and
sale of surgical drapes and gowns by a Cardinal subsidiary, Cardinal
Health 200 Inc. Terms of the settlement were not disclosed. Cardinal
representatives confirmed that the parties had reached a settlement
but declined further comment.

More here:
http://www.bizjournals.com/columbus/stories/2006/10/30/daily6.html

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Millennium Pharmaceuticals, Inc. (Public, NASDAQ:MLNM)

Millennium Pharmaceuticals, Inc. (Public, NASDAQ:MLNM)

CIBC World Markets 17th Annual Healthcare Conference to Webcast
Millennium Presentation

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company
based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for
Injection, a novel cancer product, and has a robust clinical
development pipeline of product candidates. The Company's research,
development and commercialization activities are focused in two
therapeutic areas: oncology and inflammation. By applying its
knowledge of the human genome, understanding of disease mechanisms and
industrialized drug discovery platform, Millennium is developing an
exciting pipeline of innovative product candidates

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - MedImmune, Inc. (Public, NASDAQ:MEDI)

MedImmune, Inc. (Public, NASDAQ:MEDI)

MedImmune to Present at the CIBC World Markets 17th Annual Healthcare
Conference and ViroPharma to Present at the Cowen and Company Annual
Global Healthcare Conference

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Abraxis BioScience, Inc. (Public, NASDAQ:ABBI)

Abraxis BioScience, Inc. (Public, NASDAQ:ABBI)

Abraxis BioScience Launches New Abraxane Patient Assistance Program
Comprehensive Program Provides Access to Care for Cancer Patients

Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global
biopharmaceutical company today announced the launch of the Abraxis
Patient Access Program (APAP), a comprehensive patient assistance
program for cancer patients being treated with ABRAXANE® (paclitaxel
protein-bound particles for injectable suspension) (albumin-bound).
Through APAP, financially eligible cancer patients in need of
treatment with ABRAXANE will receive access to the drug at no cost.
This new program, which replaces the previous ABRAXANE patient
assistance programs, makes it possible for financially eligible
cancer patients to receive assistance in all instances where
ABRAXANE has been prescribed.

"Through our new patient assistance program, we will be able to
provide eligible cancer patients with ABRAXANE at no cost," said
Patrick Soon-Shiong, chairman and chief executive officer of Abraxis
BioScience. "Since its launch in 2005, over 20,000 patients with
cancer have received ABRAXANE. With nearly 1.4 million people in the
United States estimated to be diagnosed with cancer in 2006, it is
important for patients to be able to receive the best possible
treatment. We are committed to ensuring there are no cost barriers
for cancer patients who may benefit from treatment with ABRAXANE."

Access to this program is available through the Abraxis Resource
Center (ARC of Support), a comprehensive program that provides a
broad range of services caring for patients being treated with
ABRAXANE. This new program offers two distinct access points for
cancer patients:

ABRAXANE at no cost to eligible uninsured patients with a household
adjusted gross income of less than $75,000 per year.
Replacement of ABRAXANE at no cost for physicians treating an
eligible insured patient, who requires additional financial support
following a denied insurance claim.
"Since the FDA approval of ABRAXANE in January 2005, we have
provided reimbursement and product information support for
physicians and their patients. Our dedication to this endeavor has
not wavered. With the launch of this new program, we are now able to
provide expanded reimbursement support to more cancer patients,"
said Carlo Montagner, president of Abraxis Oncology, a division of
Abraxis BioScience.

Physicians who wish to enroll a patient in the program should call
the ARC of Support at 1-800-564-0216, option three. For more
information about ABRAXANE and the services provided by ARC of
Support including APAP, please visit www.abraxane.com.

About Breast Cancer

According to the American Cancer Society, breast cancer is the most
common cancer among women, other than skin cancer, and is the second
leading cause of cancer death in women in the United States. The
risk of having breast cancer for a woman sometime during her life is
about one in eight. In 2006 alone, an estimated 213,000 new cases of
breast cancer are expected to occur in women, and an estimated
41,000 women are expected to die from the disease.

About ABRAXANE®

The U.S. Food and Drug Administration approved ABRAXANE® for
Injectable Suspension (paclitaxel protein-bound particles for
injectable suspension) (albumin-bound) in January 2005 for the
treatment of breast cancer after failure of combination chemotherapy
for metastatic disease or relapse within six months of adjuvant
chemotherapy. Prior therapy should have included an anthracycline
unless clinically contraindicated. For the full prescribing
information for ABRAXANE® please visit www.abraxane.com.

About Abraxis BioScience, Inc.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical
company dedicated to meeting the needs of critically ill patients.
The company develops, manufactures and markets one of the broadest
portfolios of injectable products and leverages revolutionary
technology such as its nab™ platform to discover and deliver
breakthrough therapeutics that transform the treatment of cancer and
other life-threatening diseases. The first FDA approved product to
use this nab platform, ABRAXANE®, was launched in 2005 for the
treatment of metastatic breast cancer. Abraxis trades on the NASDAQ
Stock Market under the symbol ABBI. For more information about the
company and its products, please visit www.abraxisbio.com.

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Tuesday, November 07, 2006

Biotech News - Sinovac Biotech Ltd. (Public, AMEX:SVA)

Sinovac Biotech Ltd. (Public, AMEX:SVA)

Sinovac Biotech Ltd. Engages The Ruth Group as Investor Relations
And Public Relations Counsel

Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of
biopharmaceutical products in China, announced today that it has
engaged The Ruth Group (TRG), based in New York City, to serve as
the Company's investor relations and public relations counsel.




Mr. Weidong Yin, President and CEO of Sinovac, stated, "We expect
that The Ruth Group will play a major role in facilitating
communications with Sinovac's U.S. investor base. Given their strong
and broad experience in the biotechnology and pharmaceutical
sectors, their familiarity with the information needs of the
investment and media communities, and their time zone availability,
we anticipate that they will add value by Sinovac's communications
program."

Carol Ruth, President and CEO of The Ruth Group, Inc., said, "We are
pleased to add Sinovac to our quality base of healthcare clients for
which we provide investor and public relations counsel and best-in-
class program implementation."

About The Ruth Group

Consistently ranked as one of the top U.S. financial IR/PR agencies,
The Ruth Group, based in New York, focuses on serving the
communications needs of biotechnology, pharmaceutical, medical
device, technology and semiconductor companies. Services include
investor relations, public relations, management counsel, corporate
positioning, pre-IPO public relations programs, media relations and
venture capital relations. For more information visit
http://www.theruthgroup.com .

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacture and
commercialization of vaccines that protect against human infectious
diseases. Sinovac's vaccines include Healive(TM) (hepatitis A),
Bilive(TM) (combined hepatitis A and B) and Anflu(TM) (influenza).
Sinovac is currently developing human vaccines against the H5N1
strain of pandemic influenza, Japanese encephalitis and SARS.
Additional information about Sinovac is available on its website,
http://www.sinovac.com . To be added to our distribution list,
please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These
statements are made under the "safe harbor" provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These forward-
looking statements can be identified by words or phrases such
as "will," "expects," "anticipates," "future," "intends," "plans," "b
elieves," "estimates" and similar statements. Among other things,
the business outlook and quotations from management in this press
release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking
statements involve inherent risks and uncertainties. A number of
important factors could cause actual results to differ materially
from those contained in any forward-looking statement. Sinovac does
not undertake any obligation to update any forward-looking
statement, except as required under applicable law

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - PDL BioPharma Inc. (Public, NASDAQ:PDLI) -

PDL BioPharma Inc. (Public, NASDAQ:PDLI) -

PDL BioPharma Announces November 2 Webcast of Third Quarter 2006
Financial Results Conference Call

PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI - News) today announced that
it will release its financial results for the third quarter 2006
following the close of the U.S. financial markets on Thursday,
November 2, 2006. PDL will hold a conference call to discuss these
financial results, its commercial and clinical activities and its
forward-looking information and guidance at 4:30 p.m. Eastern time
on November 2, 2006.


A live webcast of the conference call will be available through the
PDL website: www.pdl.com . Please connect to this website at least
15 minutes prior to the live webcast to allow time for any software
download that may be needed to hear the webcast. Financial and
statistical information to be discussed in the call will be
available on the PDL website immediately prior to the commencement
of the call. A replay will be available at www.pdl.com starting
approximately one hour after completion of the webcast.

An audio replay will also be available by telephone from
approximately 6:30 p.m. Eastern time on November 2, 2006 through
6:30 p.m. Eastern time on December 3, 2006. To access the replay,
dial 888-203-1112 from inside the U.S. and 719-457-0820 from outside
the U.S.; enter conference ID number 2444267.

About PDL BioPharma

PDL BioPharma, Inc. is a biopharmaceutical company focused on
discovering, developing and commercializing innovative therapies for
severe or life-threatening illnesses. The company currently markets
and sells a portfolio of leading products in the acute-care hospital
setting in the United States and Canada and generates royalties
through licensing agreements with top-tier biotechnology and
pharmaceutical companies based on its pioneering antibody
humanization technology. Currently, PDL's diverse product pipeline
includes investigational compounds in Phase 2 or Phase 3 clinical
development for inflammation and autoimmune diseases, cardiovascular
disorders and cancer. The company's research platform is focused on
the discovery and development of antibodies for the treatment of
cancer and autoimmune diseases. For more information, please see
PDL's website at www.pdl.com .

NOTE: PDL BioPharma and the PDL BioPharma logo are considered
trademarks of PDL BioPharma, Inc.

---------------------------------------------------------------------
-----------
Source: PDL BioPharma, Inc.

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Myriad Genetics, Inc. (Public, NASDAQ:MYGN)

Myriad Genetics, Inc. (Public, NASDAQ:MYGN)

Myriad Genetics Announces First Quarter Fiscal 2007 Financial
Results Conference Call
SALT LAKE CITY Myriad Genetics, Inc. (NASDAQ:MYGN) has arranged a
conference call with the management team to provide a company
update. Peter Meldrum, President and Chief Executive Officer will
host the call along with Jay Moyes, Chief Financial Officer, Gregory
Critchfield, M.D., President of Myriad Genetic Laboratories, Inc.
and Adrian Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc.

DATE: November 7, 2006
TIME: 10:00 am ET
DOMESTIC DIAL-IN: (888) 589-2820
INTERNATIONAL DIAL-IN: (706) 634-2173
CONFERENCE ID# 9681049
(Please dial in approximately 10 minutes before the call is
scheduled to begin)

A press release will be issued at 6:30 am ET on November 7, 2006.
Replay of the call will be available from two hours after the call
through November 14th by dialing (800) 642-1687 or (706) 645-9291,
and entering conference ID number 9681049.

A live audio Webcast will be available at: www.myriad.com

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Monday, November 06, 2006

Biotech News - Trinity Biotech plc (ADR) (Public, NASDAQ:TRIB)

Trinity Biotech plc (ADR) (Public, NASDAQ:TRIB)

Trinity Biotech Announces Quarter 3 Results Revenues Increase 25%
and EBITDA Exceeds US$5 Million

October 26, 2006 -- Trinity Biotech plc (NASDAQ: TRIB) (DUBLIN:
TRIB.I), a leading developer and manufacturer of diagnostic products
for the point-of-care and clinical laboratory markets, today
announced results for the quarter ended September 30, 2006.

Revenues in quarter 3 2006 increased 25% to US$33.3 million compared
to US$26.7 million in quarter 3 2005. During the same period
operating profit before share option expenses increased from US$2.2
million to US$3.3 million. Profit for the period increased from
US$1.5 million in quarter 3 2005 to US$2.6 million, representing an
increase of 71%.

Revenues for the nine months by key product area were as follows :

2005 2006
--------------- ---------------
Q1 – Q3 Q1 – Q3
--------------- ---------------
US$000 US$000 %
Increase
--------------- --------------- -----------
--

--------------- --------------- -----------
--
Clinical Chemistry 6,731 11,128
65.3%
--------------- --------------- -----------
--
Haemostasis 21,490 29,828
38.8 %
--------------- --------------- -----------
--
Infectious Diseases 33,130 32,109
(3.1)%
--------------- --------------- -----------
--
Point of Care 9,157 12,281
34.1 %
--------------- --------------- -----------
--
Total 70,508 85,346
21.0 %
--------------- --------------- -----------
--

Revenues for the nine months by geographical location were as
follows :
2005 2006
--------------- ---------------
Q1 – Q3 Q1 – Q3
--------------- ---------------
US$000 US$000 %
Increase
--------------- --------------- -----------
---

--------------- --------------- -----------
---
USA 36,200 42,402
17.1%
--------------- --------------- -----------
---
Europe 18,339 23,957
30.6%
--------------- --------------- -----------
---
Asia / Africa 15,969 18,987
18.9%
--------------- --------------- -----------
---
Total 70,508 85,346
21.0%
--------------- --------------- -----------
---

Gross profit for the quarter amounted to US$15.3 million,
representing a gross margin of 46.0%. This compares to a gross
margin of 48.1% for the same period in 2005 and 48.2% for Quarter 2.
The reduction in gross margin is associated with the recent
bioMerieux haemostasis acquisition which is comparable with the
Trinity haemostasis business and has inherently lower gross margins
than the Point of Care, Clinical Chemistry and Infectious Disease
product lines.
R&D expenses are broadly consistent with the same period last year
at US$1.7 million. The increase in selling, general and
administrative expenses from US$9.2 million in 2005 to US$10.3
million in the current quarter is primarily attributable to the
impact of the recent bioMerieux haemostasis acquisition.

The net effect of the above was an operating profit before share
options of US$3.3 million for the quarter compared to US$2.2 million
for the same period last year which represents margins of 9.9% and
8.1% respectively.

Commenting on the results, Rory Nealon, Chief Financial Officer,
said, "Our operating margin has increased from 8.1% in 2005 and 8.6%
last quarter to 9.9% in the current quarter. This is reflected in
our EPS which has increased by 18% from 11.4 cents in the previous
quarter to 13.5 cents this quarter and by 38% over the same period
in 2005. This significant improvement in profitability has primarily
resulted from the increased sales volumes created by the recent
bioMerieux acquisition. It has also resulted in an increase in our
EBITDA from US$3.6 million last quarter to US$5.1 million in the
current quarter."

Ronan O'Caoimh, CEO, commented, "The completion of the bioMerieux
haemostasis acquisition has had a significant impact on the
profitability and scale of Trinity. The Haemostasis product line
represented 35% of total sales in quarter 3 and we anticipate that
this will continue to grow as the bioMerieux related revenues
increase in quarter 4.

We are also pleased to announce that we have just acquired the
French distribution business of Nephrotek for a consideration of
US$730,000. The acquired distribution business is based in Paris and
currently distributes Trinity's product lines to the French market.
This acquisition will enable Trinity to sell directly in France
which is one of the largest diagnostics markets in Europe. Trinity
is now selling directly in the USA, Germany, the UK and France and
through a combination of distributors in approximately 75 other
countries around the world. Trinity plans to integrate the French
activities of its recently acquired bioMérieux haemostasis business
into this new operation which will increase the margins earned by
Trinity on these sales and enable us to further drive growth within
this market.

Trinity is also pleased to announce that it has recently recruited
Mr. David Oxley as Corporate Vice President of Point of Care and OTC
Business. David was previously VP of Government Affairs with
Orasure.

Forward-looking statements in this release are made pursuant to
the "safe harbor" provision of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that such forward-
looking statements involve risks and uncertainties including, but
not limited to, the results of research and development efforts, the
effect of regulation by the United States Food and Drug
Administration and other agencies, the impact of competitive
products, product development commercialisation and technological
difficulties, and other risks detailed in the Company's periodic
reports filed with the Securities and Exchange Commission.

Trinity Biotech develops, acquires, manufactures and markets over
500 diagnostic products for the point-of-care and clinical
laboratory segments of the diagnostic market. The broad line of test
kits are used to detect infectious diseases, sexually transmitted
diseases, blood coagulation disorders, and autoimmune diseases.
Trinity Biotech sells worldwide in over 80 countries through its own
salesforce and a network of international distributors and strategic
partners. For further information please see the Company's website:
www.trinitybiotech.com.

Trinity Biotech plc
Consolidated Statements of Income

(US$000's except Three Months Three Months Nine Months Nine
Months
share data) Ended Ended Ended
Ended
September September September
September
30, 2006 30, 2005 30, 2006 30,
2005
(unaudited) (unaudited) (unaudited)
(unaudited)

Revenues 33,319 26,740 85,346
70,508

Cost of sales (17,962) (13,842) (44,296)
(36,470)
Cost of sales –
inventory write
off - -
(5,800) -
Cost of sales –
share based
payments (23) (29)
(72) (80)
------------ ------------ ------------ --------
----

Gross profit 15,334 12,869 35,178
33,958
Gross profit
before inventory
write off 15,334 12,869 40,978
33,958

Other operating
income 36 60
157 186

Research &
development
expenses (1,738) (1,610) (4,696)
(4,290)
S,G&A expenses (10,344) (9,172) (28,904)
(24,653)
Indirect share
based payments (330) (307) (915)
(966)
------------ ------------ ------------ --------
----

Operating profit 2,958 1,840 820
4,235
Operating profit
before inventory
write off 2,958 1,840 6,620
4,235

Financial income 331 70
796 300
Financial expenses (982) (270) (1,724)
(731)
------------ ------------ ------------ --------
----
Net financing
costs (651) (200) (928)
(431)
------------ ------------ ------------ --------
----

Profit / (Loss)
before tax 2,307 1,640 (108)
3,804

Income tax
(expense) /
credit 244 (148) 1,786
(392)
------------ ------------ ------------ --------
----

Profit / (Loss)
for the period 2,551 1,492 1,678
3,412
Profit for the
period before
inventory write
off 2,551 1,492 5,906
3,412

Earnings per ADR 13.8 10.0 9.7
23.5

Earnings per ADR
before inventory
write off 13.8 10.0 34.1
23.5

Diluted earnings
per ADR 13.5 9.6 9.7
23.0
Diluted earnings
before inventory
write off 13.5 9.6 33.2
23.0

Weighted average
no. of shares
used in computing
earnings per
share 73,995,302 59,402,312 69,260,423
58,032,535

The above financial statements have been prepared in accordance with
the
principles of International Financial Reporting Standards and the
Company's
accounting policies but does not constitute an interim financial
report as
defined in IAS34 (Interim Financial Reporting).

Trinity Biotech plc
Consolidated Balance Sheet

December 31,
September 30,
2005
2006
US$ `000
US$ `000

(unaudited)
ASSETS
Non-current assets
Property, plant and equipment 19,202
21,824
Goodwill and intangible assets 85,197
119,753
Deferred tax assets 3,277
6,713
Other assets
61 61
-------------- ---------
-----
Total non-current assets 107,737
148,351
-------------- ---------
-----

Current assets
Inventories 36,450
41,592
Trade and other receivables 20,885
34,937
Income tax receivable
649 625
Financial assets – restricted cash 9,000
15,500
Cash and cash equivalents 9,881
4,572
Derivative financial instruments -
67
-------------- ---------
-----
Total current assets 76,865
97,293
-------------- ---------
-----

-------------- ---------
-----
TOTAL ASSETS 184,602
245,644
==============
==============

EQUITY AND LIABILITIES
Equity attributable to the equity holders
of the parent
Share capital
830 967
Share premium 124,227
149,804
Retained earnings 6,280
8,946
Translation reserve
(1,622) (657)
Other reserves 3,903
4,014
-------------- ---------
-----
Total equity 133,618
163,074
-------------- ---------
-----

Current liabilities
Interest-bearing loans and borrowings 7,720
10,415
Convertible notes – interest bearing 7,203
3,657
Income tax payable 260
1,816
Trade and other payables 12,768
19,336
Other financial liabilities 3,707
3,074
Derivative financial instruments
44 -
Provisions
199 100
-------------- ---------
-----
Total current liabilities 31,901
38,398
-------------- ---------
-----

Non-current liabilities
Interest-bearing loans and borrowings 10,369
32,970
Convertible notes – interest bearing
1,836 -
Other tax payable
48 52
Other payables 102
2,632
Deferred tax liabilities 6,728
8,518
-------------- ---------
-----
Total non-current liabilities 19,083
44,172
-------------- ---------
-----
TOTAL LIABILITIES 50,984
82,570
-------------- ---------
-----

-------------- ---------
-----
TOTAL EQUITY AND LIABILITIES 184,602
245,644
==============
==============

The above financial statements have been prepared in accordance with
the
principles of International Financial Reporting Standards and the
Company's
accounting policies but does not constitute an interim financial
report as
defined in IAS34 (Interim Financial Reporting).

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Allergan, Inc. (Public, NYSE:AGN)

Allergan, Inc. (Public, NYSE:AGN)

Allergan profit falls in 3Q, plans to buy French company
Los Angeles Business from bizjournals - November 1, 2006
Print this Article Email this Article Reprints RSS Feeds Most Viewed
Most Emailed
Allergan Inc.'s third quarter profit was down because of charges due
to its March buyout of Inamed, and it announced plans to buy Paris'
Groupe Corneal Laboratoires for $216 million, the company said
Wednesday.

Revenue was $806.8 million, up 32 percent from $611.4 million in the
year-ago period.

More:
http://www.bizjournals.com/losangeles/stories/2006/10/30/daily36.html

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Teva Pharmaceutical Industries Ltd (ADR) (Public, NASDAQ:TEVA)

Teva Pharmaceutical Industries Ltd (ADR) (Public, NASDAQ:TEVA)

Mundipharma Receives Boost to European Oxycontin Patent Position;
Teva Withdraws Challenge from European Patent Office

Mundipharma International Ltd announces a strengthening of its
position with respect to European patents on its leading product,
OxyContin® (oxycodone HCl controlled-release) tablets, following an
agreement between Purdue Pharma L.P. and its associated companies
and Teva Pharmaceuticals that has led to the withdrawal by Teva
Pharmaceuticals Europe B.V. of its challenge to OxyContin® patents
in the European Patent Office and cancellation of the patent
infringement case that was pending in the Netherlands District Court
of the Hague.

Teva's withdrawal of its European challenge and cancellation of its
infringement case involving OxyContin® come after Teva recognised
the validity of the OxyContin® patents pursuant to an agreement with
the Purdue companies executed on August 29, 2006. Under the terms of
that agreement, Teva also admits that the OxyContin® patents are
infringed by Teva's extended-release oxycodone products. In the
United States, Teva will discontinue sales of its generic version of
OxyContin® subject to certain contingencies contained in its
agreement with Purdue that permit Teva to remain on the market at
least through March 31, 2007.

The Teva agreement follows a decision by the United States Court of
Appeals for the Federal Circuit that vacated a previous trial court
finding of unenforceability: "The patents being asserted in favour
of OxyContin® have been properly examined and rightly granted. We
will vigorously defend the rights they convey against anyone who
attempts to infringe on those rights" said Åke Wikström, Regional
Director, Europe, Mundipharma International Ltd.

Separately, Endo Pharmaceuticals Inc. has agreed that its extended-
release oxycodone products infringe certain of Purdue's, and its
associated companies', OxyContin® patents in the U.S., Europe and
Canada and that it will not dispute the validity of any of Purdue's,
or its associated companies', patents anywhere in the world. Consent
judgments reflecting some of the terms of the Teva and Endo
settlements have been signed and entered by a federal judge of the
United States District Court for the Southern District of New York.

As a matter of good public health policy, it is vital that patents
awarded for scientific and medical inventions be respected. Patents
protect inventors and, in the fields of science and medicine, they
protect patients as well, who benefit from the fruits of medical
research. The inventions protected by patents help to fund further
research and thus lead to additional progress towards finding and
providing the best possible medicines to relieve human suffering.

Mundipharma's independent associated companies invested in excess of
EUR250 million to develop OxyContin® and continue to commit millions
of Euros to the ongoing research and development of important new
medicines in fields such as pain management, haemato-oncology and
respiratory conditions.

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Vertex Pharmaceuticals Incorporated (Public, NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated (Public, NASDAQ:VRTX)

Vertex presents mixed results in hepatitis C drug
30th October 2006
By Victoria Harrison
Vertex has presented mixed results from its phase Ib trial of its
hepatitis C drug, saying that some patients still had the virus when
combined with ribavirin.
The study examined Vertex's investigational hepatitis C virus
protease inhibitor, telaprevir in combination with pegylated
interferon (peg-IFN) with or without ribavirin.

The hepatitis C virus was suppressed in patients when pegylated
interferon was added to telaprevir in the phase Ib clinical study

More here: http://www.pharmaceutical-business-review.com/article_news.asp?guid=47B35064-373A-4E2F-A667-8B3538B4911F

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Biogen Idec Inc. (Public, NASDAQ:BIIB)

Biogen Idec Inc. (Public, NASDAQ:BIIB)

In earnings news, Biogen Idec (NASDAQ:BIIB) announced third-quarter
net profit of $156.6 million, or 45 cents per share, from $27.2
million, or eight cents per share, in the prior year. Excluding items,
earnings surged 67 percent to 60 cents per share, or well above the
consensus analysts' view of 49 cents per share. Total revenue at the
biotech firm climbed 18 percent to $703.5 million. Looking forward,
the company now expects full-year earnings per share of more than
$2.20, outpacing Wall Street's current per-share view of $2.09. The
stock has rocketed nearly six percent higher in the first few minutes
of trading.

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Amgen, Inc. AMGN Amgen Foundation Launches $25 Million Amgen Scolars Program

Amgen, Inc. (Public, NASDAQ:AMGN)

Amgen, Inc. AMGN Amgen Foundation Launches $25 Million Amgen Scolars
Program.

Amgen Foundation Launches $25 Million Undergraduate Research Program
Amgen Scholars Will Provide Hands-on Science Research Experience at
10 of the Nation's Premier Universities

THOUSAND OAKS, Calif. Oct. 19, 2006--As part of its mission to
advance science education, the Amgen Foundation today announced its
partnership with 10 of the nation's leading universities to provide
hundreds of selected undergraduate students an opportunity to engage
in a fully funded, hands-on research experience each summer.

Amgen Scholars is a $25 million, eight-year program that will
provide research experience for students interested in pursuing a
graduate degree and a career in science. For the first phase of the
program, which extends through 2010, each of the 10 program partners
will receive $1 million over the next four years. Each institution
is charged with selecting participants from both their own student
body as well as from other accredited four-year colleges and
universities in the United States, Puerto Rico and other U.S.
Territories.

The 10 program partners are:

California Institute of Technology (Caltech)
Columbia University/Barnard College
Howard University
Massachusetts Institute of Technology (MIT)
Stanford University
University of California, Berkeley
University of California, Los Angeles
University of California, San Diego
University of California, San Francisco
University of Washington

"The experience of hands-on research is an extraordinarily effective
way to encourage undergraduate students to pursue careers in
science," said Susan Hockfield, president of MIT. "By providing
access to exciting research programs and dynamic industry leaders,
the innovative Amgen Scholars program will engage and inspire young
people - at a time when the education of the next generation of
scientists is more important than ever."

MIT, which has long been at the forefront of undergraduate research
programming, will serve as the national program office and will play
a leading role in providing coordination, technical oversight, and
student outreach for the program. As the national program office,
MIT will receive an additional $1 million over the next four years.

Amgen Scholars will participate in research projects, scientific
seminars and work under some of the nation's top academic
scientists. All participating students also will have the
opportunity to take part in an annual mid-summer, three-day
symposium in California. At the symposium, students will have the
chance to hear firsthand from leading scientists working in industry
and academia, and to network with other Amgen Scholars from across
the nation.

Financial support for students is a critical component of the
program, and thus eligible students regardless of their financial
status are able to participate. Students will receive a competitive
stipend along with room, board and a travel allowance, which
includes travel to and from the university and the symposium.

"At Amgen, we believe we have an important responsibility to inspire
and prepare the next generation of scientists," said Jean Lim,
president, Amgen Foundation. "In partnership with some of our
nation's top research universities, we hope to strengthen
undergraduate science education by increasing the number of
available research opportunities for students. Our hope is that this
program will be a pivotal experience that will encourage students to
pursue further education and training in the sciences."

The Amgen Foundation is committed to advancing science education
through its support of educational programs that provide hands-on
science experiences for students at all levels, in addition to
focusing on teacher quality and professional development at the K-12
levels. Earlier this year, the Foundation announced a $5 million,
five-year partnership with Teach For America to support a program
aimed at doubling the number of college math and science graduates
who join Teach For America by 2010. The goal is to improve the
quality of math and science education in America's underserved
public schools. Additionally, the Amgen Foundation supports several
local, regional and national programs to support and reinvigorate
science education in and out of the classroom.

For more information about Amgen Scholars, please visit
www.amgenscholars.com

About the Amgen Foundation

The Amgen Foundation (www.amgen.com/citizenship/overview.html) seeks
to advance science education; improve patient access to quality
care; and strengthen the communities where Amgen staff members live
and work. Since 1991, the Foundation has made $70 million in grants
to local, regional and national non-profit organizations that impact
society in inspiring and innovative ways. It has also supported
disaster relief efforts both domestically and internationally.

CONTACT: The Amgen Foundation

SOURCE: The Amgen Foundation

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Genentech, Inc. DNA Genentech Repeats as 'Fastest Company in Silicon Valley'

Genentech, Inc. DNA

Genentech Repeats as 'Fastest Company in Silicon Valley' in 2006
Comerica Corporate Challenge at Metro Silicon Valley Marathon

SAN JOSE, Calif., Nov. 3 -- Top performing companies in Silicon
Valley each year are recognized as among the "Fastest Growing." Now,
for the second year in a row, bio-tech trailblazer Genentech Inc.,
has been crowned the "Fastest Company in Silicon Valley," not for
its business prowess but for the skills of its half-marathon runners
in the Comerica Corporate Challenge at the Metro Silicon Valley
Marathon.

In the second annual Comerica Corporate Challenge, Genentech's
winning time of 4 hours, 45 minutes, 25 seconds for the combined
times of its top three half-marathon runners was 29 minutes slower
than its winning team time in the inaugural challenge a year ago,
but good enough to top other fleet- footed corporate teams. The
Comerica Cup will be displayed at its headquarters location again
for one year.

The race was held in downtown San Jose on Oct. 29. Comerica Bank won
the prize for the largest corporate running team.

One of Comerica's runners, Charles McCarroll, a vice president in
the middle market division in San Jose, had the fastest time among
the corporate teams, at 1 hour, 26 minutes, 34 seconds.

On behalf of the winning corporate teams, $2,250 was donated to The
Health Trust, a Bay Area non-profit organization.

In addition to Genentech, the 20 companies that competed in the
Comerica Corporate Challenge included runners from Apple Computer,
Cisco, Hewlett- Packard, IBM, Lockheed Martin, Yahoo! and the law
firm of Baker & McKenzie. Team members had a choice of running or
walking in the marathon, half-marathon or 5K run/walk. The entire
Metro Silicon Valley Marathon featured more than 3,000 runners from
10 countries and 25 states.

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Serono S.A. (ADR) (Public, NYSE:SRA)

Serono S.A. (ADR) (Public, NYSE:SRA)

Germany's Merck gets US antitrust nod for Serono

WASHINGTON, Oct 31 (Reuters) - U.S. antitrust authorities have
approved German drugmaker Merck KGaA's (MRCG.DE: Quote, Profile,
Research) takeover of biotech firm Serono SA (SEO.VX: Quote,
Profile, Research), the U.S. Federal Trade Commission said in a
notice on Tuesday.

U.S. officials closed their review of the transaction without taking
any action to block it, the agency said.

More here:
http://today.reuters.com/news/articleinvesting.aspx?view=CN&storyID=2006-10-31T163849Z_01_N31198577_RTRIDST_0_HEALTH-SERONO-ANTITRUST.XML&rpc=66&type=qcna

Serono posts near 20 pct increase in third quarter net profit

The Swiss biotechnology and pharmaceuticals company Serono reported
third quarter net income of 170.6 million dollars (136.1 million
euros) for the third quarter, a 19.8 percent increase over the same
period last year.

Total revenue in the third quarter rose 9.5 percent over the same
period last year to 699.1 million dollars, the company said in a
statement.

Sales of Serono's flagship multiple sclerosis drug Rebif totalling
374.8 million dollars accounted for more than half of the Swiss
company's revenues.

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://famouspeople.wordpress.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Invitrogen Corporation (Public, NASDAQ:IVGN)

Invitrogen Corporation (Public, NASDAQ:IVGN)

Stratagene Ordered to Shell Out Triple the Amount Previously Awarded
in the Invitrogen Lawsuit

In a patent infringement case, a U.S. court awarded Invitrogen $16.2
million in damages.

On July 25, 2006, the jury found that Stratagene had willfully
infringed on Invitrogen's valid 4,981,797 patent by making and selling
its competent E. coli cell products.

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Genzyme Corporation (Public, NASDAQ:GENZ)

Genzyme Corporation (Public, NASDAQ:GENZ)

Genzyme sells new gene test for cystic fibrosis

The biotechnology company said the diagnostic test can detect about
98 percent of about 1,200 disease-causing variations in a gene, in
which mutations are linked to cystic fibrosis.

BioMarin Announces Marketing Approval for Aldurazyme in Japan

NOVATO, Calif., Oct. 31 -- BioMarin
Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that
Japan's
Ministry of Health, Labor, and Welfare (MHLW) has granted marketing
authorization for Aldurazyme(R) (laronidase), the first specific
treatment
approved in Japan for patients with the genetic disease
mucopolysaccharidosis I (MPS I). Aldurazyme was approved in Japan as
an
orphan drug.
"I am very pleased that enzyme replacement therapy with
Aldurazyme has
finally been approved in Japan for the treatment of MPS I," stated
Yoshikatsu Eto, M.D., Chairman and Professor in the Department of
Pediatrics at Tokyo Jikei University Hospital located in Tokyo,
Japan.
"This is an important milestone for Japanese MPS I patients and their
treating physicians who now have an effective treatment for this
debilitating and life-threatening disease."
Aldurazyme was developed in partnership between BioMarin and
Genzyme
and was approved in the United States and the European Union in
April and
May 2003, respectively. Pursuant to the joint venture, BioMarin is
responsible for manufacturing Aldurazyme and Genzyme is responsible
for its
commercialization. All expenses and profits and are shared equally
between
the companies.

http://tech.groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://famouspeople.wordpress.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Gilead Sciences, Inc. (Public, NASDAQ:GILD)

Gilead Sciences, Inc. (Public, NASDAQ:GILD)

Gilead Sciences Extends Expiration Date for Tender Offer for Myogen
Until November 13, 2006
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:
GILD) today announced that it has extended the initial expiration
date for its previously announced tender offer for all of the
outstanding shares of common stock of Myogen, Inc. (Nasdaq: MYOG) to
Monday, November 13, 2006 at one minute following 11:59 p.m. New
York City time (midnight). The originally announced expiration date
for the tender offer, Friday, November 10, 2006, is a federal
employee holiday. Therefore, the initial expiration date for the
tender offer is being corrected and extended in order to ensure that
the tender offer will remain open for the full minimum twenty
business-day period required under Rule 14e-1 of the Securities
Exchange Act of 1934, as amended.

As of October 31, 2006, approximately 265,685 shares of Myogen
common stock had been tendered and not withdrawn from the offer. The
tender offer is expected to close by the end of the fourth quarter
of 2006, subject to customary closing conditions.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company's mission is to advance the care of
patients suffering from life-threatening diseases worldwide.
Headquartered in Foster City, California, Gilead has operations in
North America, Europe and Australia. For more information on Gilead
Sciences, please visit the company's website at www.gilead.com or
call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

http://groups.yahoo.com/group/biotech-news/
http://www.arizonabiotech.com/
http://famouspeople.wordpress.com/

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> Your email settings:
Individual Email | Traditional

<*> To change settings online go to:
http://groups.yahoo.com/group/biotech-news/join
(Yahoo! ID required)

<*> To change settings via email:
mailto:biotech-news-digest@yahoogroups.com
mailto:biotech-news-fullfeatured@yahoogroups.com

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/